際際滷

際際滷Share a Scribd company logo
Mark Davison
息 John Steven Hernandez
Agenda
 What are the global issues?
 What anti-counterfeiting technologies could work
everywhere?
 How do we best serve developing countries?
 What do the patients want?
mark.davison@bluespherehealth.com 2
No Man is an Island
mark.davison@bluespherehealth.com 3
How We See the World:
People or Territory?
mark.davison@bluespherehealth.com 4
World Map by Land Area
mark.davison@bluespherehealth.com 5
息 SASI Group (University of Sheffield) and Mark Newman (University of Michigan)
Headline Counterfeit Flows
mark.davison@bluespherehealth.com 6
息 SASI Group (University of Sheffield) and Mark Newman (University of Michigan)
Response: Logistics-Based Security
 Control the product
flow, control the crime
 Serialization, pedigree,
RFID etc.
 Tech-centric approaches
 Infrastructure
requirements
 Pay-offs in patient safety,
logistics efficiency
 Reduces opportunity for
large-scale crime
 Provides a modular,
scalable, global
framework
mark.davison@bluespherehealth.com 7
Deadliest Counterfeit Flows
mark.davison@bluespherehealth.com 8
息 SASI Group (University of Sheffield) and Mark Newman (University of Michigan)
InternalCounterfeits
mark.davison@bluespherehealth.com 9
息 SASI Group (University of Sheffield) and Mark Newman (University of Michigan)
Logistics is Only One Aspect
 Tech-centric approaches are difficult in developing
countries
 Doesnt deal with locally-produced fakes
 Wider approach is needed
mark.davison@bluespherehealth.com 10
mark.davison@bluespherehealth.com 11
Global Share of Land
mark.davison@bluespherehealth.com 12
息 SASI Group (University of Sheffield) and Mark Newman (University of Michigan)
 Share of Population
mark.davison@bluespherehealth.com 13
息 SASI Group (University of Sheffield) and Mark Newman (University of Michigan)
and Share of Poverty
mark.davison@bluespherehealth.com 14
息 SASI Group (University of Sheffield) and Mark Newman (University of Michigan)
Who Pays the Costs of
Anti-Counterfeiting?
The costs associated with implementing E-pedigree will
be too high for some California pharmacists to absorb.
This means even more small business pharmacies will
be put in jeopardy. This will harm patient access to
prescription drugs and consultation care.
National Community Pharmacists Association, Dec 2007
http://www.pharmacy.ca.gov/meetings/minutes/2007/07_dec_enf1.pdf
mark.davison@bluespherehealth.com 15
Who Pays the Costs of
Anti-Counterfeiting?
The costs associated with implementing E-pedigree will
be too high for some California pharmacists to absorb.
This means even more small business pharmacies will
be put in jeopardy. This will harm patient access to
prescription drugs and consultation care.
National Community Pharmacists Association, Dec 2007
http://www.pharmacy.ca.gov/meetings/minutes/2007/07_dec_enf1.pdf
mark.davison@bluespherehealth.com 16
Who Pays the Costs of
Anti-Counterfeiting?
The costs associated with implementing E-pedigree will
be too high for some California pharmacists to absorb.
This means even more small business pharmacies will
be put in jeopardy. This will harm patient access to
prescription drugs and consultation care.
National Community Pharmacists Association, Dec 2007
http://www.pharmacy.ca.gov/meetings/minutes/2007/07_dec_enf1.pdf
mark.davison@bluespherehealth.com 17
#8
GDP
Worldwide.
If California
cant afford it,
who can?
Ubiquitous Anti-Counterfeiting
Technology Must Be:
 Secure
 Easy to use with minimal / no training
 Physically robust
 Low entry costs (or subsidized)
 Flexible and scalable
 Upgradable and Replaceable
mark.davison@bluespherehealth.com 18
mark.davison@bluespherehealth.com 19
Role of the State
 Centralized solutions may be the best option
 Europe, USA, China, Brazil etc.
 Not all states will cope with serialization
 Heavy subsidy and technical help needed
 Scalable approaches to aid phased uptake
 Supportive, non-punitive environment
mark.davison@bluespherehealth.com 20
But
Share of Public Health Spending
mark.davison@bluespherehealth.com 21
息 SASI Group (University of Sheffield) and Mark Newman (University of Michigan)
How About the Pharmacist?
 The last professional to touch the pack
 Trained and trainable (in anti-counterfeiting systems)
 Ubiquitous in every community?
mark.davison@bluespherehealth.com 22
Unequal Share of Pharmacists
mark.davison@bluespherehealth.com 23
息 SASI Group (University of Sheffield) and Mark Newman (University of Michigan)
Publicly-funded Healthcare and
Private Pharmacists
mark.davison@bluespherehealth.com 24
息 SASI Group (University of Sheffield) and Mark Newman (University of Michigan)
Mostly
private-sector
pharmacists
Pharmacists
Public funding
Pharmacy-Based Drug Security
 Relatively simple, logical approach
 May not work everywhere
 Not all pharmacists are equivalent
 Sometimes they are the problem not the solution
mark.davison@bluespherehealth.com 25
How About the Consumer?
 Ubiquitous
 Least trained element of the supply chain
 Most to lose if product security fails:
 We invest, but they ingest
 Very effective if given the right systems
 Communication is vital:
 Education, education, education
 Should only be the sentinel of last resort against fake
drugs
mark.davison@bluespherehealth.com 26
How to get the message across to consumers?
Share of Literacy
mark.davison@bluespherehealth.com 28
息 SASI Group (University of Sheffield) and Mark Newman (University of Michigan)
Share of Personal Computers
mark.davison@bluespherehealth.com 29
息 SASI Group (University of Sheffield) and Mark Newman (University of Michigan)
Share of Languages
mark.davison@bluespherehealth.com 30
息 SASI Group (University of Sheffield) and Mark Newman (University of Michigan)
Consequences
 Low literacy levels and high language diversity need to
be dealt with and planned for
 Dont assume that the message transmitted is the
message received
 Adapt materials and channels to local requirements
 Culture, language, taboos etc
 Use verbal communication when necessary:
 Radio, local networks, village meetings
 Reinforce the message repeatedly and frequently
mark.davison@bluespherehealth.com 31
Clue: They dont care about anti-counterfeiting technologies
mark.davison@bluespherehealth.com 32
Patients Want Safe Medicines
 Supply chain security is vital
 Customer is a useful last link for security
 Many people are too poor to have choices
 Choice of fake or real may actually be drug or no drug
 Distinctions are often blurred
 Traditional medicine versus western drugs
 Expensive versus cheap
 Genuine versus fake
mark.davison@bluespherehealth.com 33
Why Dont Drug Companies Just Concentrate on
Keeping Developed Markets Safe?
 Serialize (code) everything but only check a subset
 Developed countries, Major urban centres
 Protect (paying) patients health, share price, revenues
 Eliminate the costs and complexity of a global system!
mark.davison@bluespherehealth.com 34
Devils Advocate question!
Heres why: Share of Malaria
mark.davison@bluespherehealth.com 35
息 SASI Group (University of Sheffield) and Mark Newman (University of Michigan)
Answer!
Or Share of Tuberculosis
mark.davison@bluespherehealth.com 36
Fake tuberculosis and malaria drugs alone are estimated
to kill 700,000 people a year. Thats equivalent to four
fully laden jumbo jets crashing every day.
Julian Harris, International Policy Network, 2009
www.policynetwork.net/health/publication/keeping-it-
real-protecting-worlds-poor-fake-drugs
mark.davison@bluespherehealth.com 37
The World is Small, Disease Travels and Everyone is Connected
mark.davison@bluespherehealth.com 38
Send me an email if you want to know more about
global anti-counterfeiting issues.
Photo on title slide by John Steven Fernandez www.flickr.com/photos/stevenfernandez/2069638117/
Maps are from Worldmapper.org and Buckminster Fuller Institute
Any man's death diminishes me,
For I am involved in mankind.
And therefore never send to know
For whom the bell tolls;
It tolls for thee.
(John Donne)
mark.davison@bluespherehealth.com 39

More Related Content

Global Perspectives on Pharmaceutical Anti-Counterfeiting

  • 1. Mark Davison 息 John Steven Hernandez
  • 2. Agenda What are the global issues? What anti-counterfeiting technologies could work everywhere? How do we best serve developing countries? What do the patients want? mark.davison@bluespherehealth.com 2
  • 3. No Man is an Island mark.davison@bluespherehealth.com 3
  • 4. How We See the World: People or Territory? mark.davison@bluespherehealth.com 4
  • 5. World Map by Land Area mark.davison@bluespherehealth.com 5 息 SASI Group (University of Sheffield) and Mark Newman (University of Michigan)
  • 6. Headline Counterfeit Flows mark.davison@bluespherehealth.com 6 息 SASI Group (University of Sheffield) and Mark Newman (University of Michigan)
  • 7. Response: Logistics-Based Security Control the product flow, control the crime Serialization, pedigree, RFID etc. Tech-centric approaches Infrastructure requirements Pay-offs in patient safety, logistics efficiency Reduces opportunity for large-scale crime Provides a modular, scalable, global framework mark.davison@bluespherehealth.com 7
  • 8. Deadliest Counterfeit Flows mark.davison@bluespherehealth.com 8 息 SASI Group (University of Sheffield) and Mark Newman (University of Michigan)
  • 9. InternalCounterfeits mark.davison@bluespherehealth.com 9 息 SASI Group (University of Sheffield) and Mark Newman (University of Michigan)
  • 10. Logistics is Only One Aspect Tech-centric approaches are difficult in developing countries Doesnt deal with locally-produced fakes Wider approach is needed mark.davison@bluespherehealth.com 10
  • 12. Global Share of Land mark.davison@bluespherehealth.com 12 息 SASI Group (University of Sheffield) and Mark Newman (University of Michigan)
  • 13. Share of Population mark.davison@bluespherehealth.com 13 息 SASI Group (University of Sheffield) and Mark Newman (University of Michigan)
  • 14. and Share of Poverty mark.davison@bluespherehealth.com 14 息 SASI Group (University of Sheffield) and Mark Newman (University of Michigan)
  • 15. Who Pays the Costs of Anti-Counterfeiting? The costs associated with implementing E-pedigree will be too high for some California pharmacists to absorb. This means even more small business pharmacies will be put in jeopardy. This will harm patient access to prescription drugs and consultation care. National Community Pharmacists Association, Dec 2007 http://www.pharmacy.ca.gov/meetings/minutes/2007/07_dec_enf1.pdf mark.davison@bluespherehealth.com 15
  • 16. Who Pays the Costs of Anti-Counterfeiting? The costs associated with implementing E-pedigree will be too high for some California pharmacists to absorb. This means even more small business pharmacies will be put in jeopardy. This will harm patient access to prescription drugs and consultation care. National Community Pharmacists Association, Dec 2007 http://www.pharmacy.ca.gov/meetings/minutes/2007/07_dec_enf1.pdf mark.davison@bluespherehealth.com 16
  • 17. Who Pays the Costs of Anti-Counterfeiting? The costs associated with implementing E-pedigree will be too high for some California pharmacists to absorb. This means even more small business pharmacies will be put in jeopardy. This will harm patient access to prescription drugs and consultation care. National Community Pharmacists Association, Dec 2007 http://www.pharmacy.ca.gov/meetings/minutes/2007/07_dec_enf1.pdf mark.davison@bluespherehealth.com 17 #8 GDP Worldwide. If California cant afford it, who can?
  • 18. Ubiquitous Anti-Counterfeiting Technology Must Be: Secure Easy to use with minimal / no training Physically robust Low entry costs (or subsidized) Flexible and scalable Upgradable and Replaceable mark.davison@bluespherehealth.com 18
  • 20. Role of the State Centralized solutions may be the best option Europe, USA, China, Brazil etc. Not all states will cope with serialization Heavy subsidy and technical help needed Scalable approaches to aid phased uptake Supportive, non-punitive environment mark.davison@bluespherehealth.com 20
  • 21. But Share of Public Health Spending mark.davison@bluespherehealth.com 21 息 SASI Group (University of Sheffield) and Mark Newman (University of Michigan)
  • 22. How About the Pharmacist? The last professional to touch the pack Trained and trainable (in anti-counterfeiting systems) Ubiquitous in every community? mark.davison@bluespherehealth.com 22
  • 23. Unequal Share of Pharmacists mark.davison@bluespherehealth.com 23 息 SASI Group (University of Sheffield) and Mark Newman (University of Michigan)
  • 24. Publicly-funded Healthcare and Private Pharmacists mark.davison@bluespherehealth.com 24 息 SASI Group (University of Sheffield) and Mark Newman (University of Michigan) Mostly private-sector pharmacists Pharmacists Public funding
  • 25. Pharmacy-Based Drug Security Relatively simple, logical approach May not work everywhere Not all pharmacists are equivalent Sometimes they are the problem not the solution mark.davison@bluespherehealth.com 25
  • 26. How About the Consumer? Ubiquitous Least trained element of the supply chain Most to lose if product security fails: We invest, but they ingest Very effective if given the right systems Communication is vital: Education, education, education Should only be the sentinel of last resort against fake drugs mark.davison@bluespherehealth.com 26
  • 27. How to get the message across to consumers?
  • 28. Share of Literacy mark.davison@bluespherehealth.com 28 息 SASI Group (University of Sheffield) and Mark Newman (University of Michigan)
  • 29. Share of Personal Computers mark.davison@bluespherehealth.com 29 息 SASI Group (University of Sheffield) and Mark Newman (University of Michigan)
  • 30. Share of Languages mark.davison@bluespherehealth.com 30 息 SASI Group (University of Sheffield) and Mark Newman (University of Michigan)
  • 31. Consequences Low literacy levels and high language diversity need to be dealt with and planned for Dont assume that the message transmitted is the message received Adapt materials and channels to local requirements Culture, language, taboos etc Use verbal communication when necessary: Radio, local networks, village meetings Reinforce the message repeatedly and frequently mark.davison@bluespherehealth.com 31
  • 32. Clue: They dont care about anti-counterfeiting technologies mark.davison@bluespherehealth.com 32
  • 33. Patients Want Safe Medicines Supply chain security is vital Customer is a useful last link for security Many people are too poor to have choices Choice of fake or real may actually be drug or no drug Distinctions are often blurred Traditional medicine versus western drugs Expensive versus cheap Genuine versus fake mark.davison@bluespherehealth.com 33
  • 34. Why Dont Drug Companies Just Concentrate on Keeping Developed Markets Safe? Serialize (code) everything but only check a subset Developed countries, Major urban centres Protect (paying) patients health, share price, revenues Eliminate the costs and complexity of a global system! mark.davison@bluespherehealth.com 34 Devils Advocate question!
  • 35. Heres why: Share of Malaria mark.davison@bluespherehealth.com 35 息 SASI Group (University of Sheffield) and Mark Newman (University of Michigan) Answer!
  • 36. Or Share of Tuberculosis mark.davison@bluespherehealth.com 36
  • 37. Fake tuberculosis and malaria drugs alone are estimated to kill 700,000 people a year. Thats equivalent to four fully laden jumbo jets crashing every day. Julian Harris, International Policy Network, 2009 www.policynetwork.net/health/publication/keeping-it- real-protecting-worlds-poor-fake-drugs mark.davison@bluespherehealth.com 37
  • 38. The World is Small, Disease Travels and Everyone is Connected mark.davison@bluespherehealth.com 38
  • 39. Send me an email if you want to know more about global anti-counterfeiting issues. Photo on title slide by John Steven Fernandez www.flickr.com/photos/stevenfernandez/2069638117/ Maps are from Worldmapper.org and Buckminster Fuller Institute Any man's death diminishes me, For I am involved in mankind. And therefore never send to know For whom the bell tolls; It tolls for thee. (John Donne) mark.davison@bluespherehealth.com 39